Get the Stockscreener App
1.16
1.75%
0.02
After Hours:
1.16
Lucid Diagnostics Inc stock is traded at $1.16, with a volume of 544.23K.
It is up +1.75% in the last 24 hours and up +4.50% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.14
Open:
$1.15
24h Volume:
544.23K
Relative Volume:
0.58
Market Cap:
$152.07M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0741
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
+12.62%
1M Performance:
+4.50%
6M Performance:
-11.45%
1Y Performance:
+49.87%
1-Day Range:
$1.12
$1.17
1-Week Range:
$1.035
$1.17
52-Week Range:
$0.7501
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.16 | 149.45M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt? - simplywall.st
Lucid Diagnostics Stock (LUCD) Opinions on Recent Clinical Data Release - Quiver Quantitative
Lucid Diagnostics (NASDAQ:LUCD) Given New $8.25 Price Target at Ascendiant Capital Markets - MarketBeat
Ascendiant Capital Maintains Lucid Diagnostics (LUCD) Buy Recommendation - Nasdaq
Lucid Diagnostics stock price target raised to $8.25 at Ascendiant Capital By Investing.com - Investing.com South Africa
Lucid Diagnostics stock price target raised to $8.25 at Ascendiant Capital - Investing.com Canada
Lucid Diagnostics reports real-world data on esophageal test device By Investing.com - Investing.com Nigeria
Lucid Diagnostics (LUCD) Stock: Surge After Real-World EsoGuard Data Breakthrough! - parameter.io
Lucid Diagnostics (Nasdaq: LUCD) reports 95% EsoCheck success in 11,991 patients - Stock Titan
Lucid Diagnostics files for $175 mln mixed securities shelf offering - MSN
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus
A Look at Lucid Diagnostics Inc (LUCD) Shares in the Recent Past Indicates Growth - Setenews
Should I hold or sell Lucid Diagnostics Inc. stock in 2025Weekly Market Outlook & Weekly High Return Stock Opportunities - Newser
Why Lucid Diagnostics Inc. stock appeals to analysts2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Lucid Diagnostics (LUCD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lucid Diagnostics stock falls after pricing capital raise of $15M via stock offering - MSN
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% - Yahoo Finance
Is Lucid Diagnostics Inc (LUCD) positioned for future growth? - Setenews
Why Being Public Gave PavMed a Competitive Edge - Medical Device and Diagnostic industry
Get in on Lucid Diagnostics Inc’s (LUCD) buy-in window today! - Setenews
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree - PR Newswire
Ranking Lucid Diagnostics Inc. among high performing stocks via tools2025 Top Decliners & AI Powered Trade Plan Recommendations - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Developing predictive dashboards with Lucid Diagnostics Inc. dataBear Alert & Fast Gain Swing Alerts - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Live market analysis of Lucid Diagnostics Inc.Weekly Market Report & Long Hold Capital Preservation Tips - newser.com
Why retail investors favor Lucid Diagnostics Inc. stockAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
Is Lucid Diagnostics Inc. stock oversold or undervaluedMarket Growth Report & Pattern Based Trade Signal System - newser.com
Measuring Lucid Diagnostics Inc.’s beta against major indices - newser.com
Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus - TipRanks
Lucid Diagnostics’ Earnings Call: Strategic Wins Amid Challenges - MSN
Combining machine learning predictions for Lucid Diagnostics Inc.2025 Major Catalysts & Daily Volume Surge Trade Alerts - newser.com
Why Lucid Diagnostics Inc. stock is considered a top pickJuly 2025 Momentum & Community Consensus Picks - newser.com
Is Lucid Diagnostics Inc. meeting your algorithmic filter criteriaEarnings Performance Report & Weekly Momentum Stock Picks - newser.com
Lucid Diagnostics (NASDAQ:LUCD) Cut to Sell at Wall Street Zen - MarketBeat
Earnings call transcript: Lucid Diagnostics Q3 2025 reports revenue growth and strategic advancements - Investing.com Nigeria
Lucid Diagnostics Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:LUCD) 2025-11-14 - Seeking Alpha
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Eastern Progress
How supply chain issues affect Lucid Diagnostics Inc. stockJuly 2025 Setups & Daily Profit Focused Screening - Fundação Cultural do Pará
[New] Lucid Stock Price Prediction 2024, 2025 To 2050 - Exla Resources
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 20 '25 |
Buy |
1.29 |
187,098 |
242,292 |
187,098 |
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):